@media (max-width: 768px) {
                .image-container {
                    width: 100% !important;
                    float: none !important;
                    margin: 0 0 1rem 0 !important;
                }
            }
        



Image source: The Mo

Revolution Medicines (RVMD) Q3 2026 Earnings Call Transcript

Revolution Medicines, Inc. announced its financial results for the quarter ended September 30, 2026, highlighted by the U.S. Food and Drug Administration approval and commercial launch of RASONQUE (daraxonrasib) on August 26, 2026. RASONQUE is approved for adult patients with met

Revolution Medicines Reports Third Quarter 2026 Financial Results and RASONQUE Launch

Key PointsRevolution Medicines' stock has soared over 9x in three years.

Could Revolution Medicines Be a Millionaire-Maker Stock?

(RTTNews) - Revolution Medicines, Inc. (RVMD) presented new subgroup analyses from its Phase 3 RASolute 302 trial showing that RASONQUE (daraxonrasib) continued to deliver an overall survival benefit compared with chemotherapy across multiple patient groups with previously treate

RVMD's RASONQUE Shows Survival Benefit Across Key Patient Group In Metastatic Pancreatic Cancer 

(RTTNews) - Biotech and healthcare stocks attracted investor attention on Tuesday, driven by developments in clinical research, fertility care, oncology drug development and a major prenatal testing business sale. Myriad Genetics surged after agreeing to sell its Prenatal Health

Biotech Stocks Move Higher: MBRX Gains 15%, FEMY Rises 7%, RVMD Advances 7%, MYGN Surges Over 40% 

Fintel reports that on October 16, 2026, William Blair initiated coverage of Revolution Medicines (NASDAQGS:RVMD) (BIT:1RVMD) with a Outperform recommendation.Revolution Medicines, Inc., based in the United States, operates within the biotechnology industry, specifically focusing

William Blair Initiates Coverage of Revolution Medicines at Outperform

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Revolution Medicines, Inc. News